The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2019

Filed:

Dec. 19, 2016
Applicant:

University of Massachusetts, Boston, MA (US);

Inventors:

Timothy F. Kowalik, Princeton, MA (US);

Mariluz Rodriguez-Gonzalez, Worcester, MA (US);

Alexander Lagadinos, Worcester, MA (US);

Assignee:

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/522 (2006.01); A61K 31/7105 (2006.01); A61K 35/50 (2015.01); A61K 45/06 (2006.01); C12Q 1/70 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1133 (2013.01); A61K 31/522 (2013.01); A61K 31/7105 (2013.01); A61K 35/50 (2013.01); A61K 45/06 (2013.01); C12N 15/1131 (2013.01); C12Q 1/705 (2013.01); G01N 33/56994 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/315 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2333/03 (2013.01);
Abstract

The present invention relates to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-1. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.


Find Patent Forward Citations

Loading…